bluuebunny/crossref_metadata_2025_split huggingface dataset:
Motivational interviewing with individuals at risk of sex trafficking
Authors: Gerassi Lara B , Esbensen Karyn 
Published: April 2020

Summary Motivational interviewing is an evidence-based practice designed to collaboratively strengthen a person’s commitment to change. Used in a wide variety of practice settings, motivational interviewing is recommended for use with individuals who are at risk of sex trafficking when discussing sex trading or relationships with potential traffickers. However, little is known about the uses of motivational interviewing with this population in practice. The current study examined whether and how social workers who encounter individuals at risk of sex trafficking use motivational interviewing. We explored perceptions of motivational interviewing use, applicability, and engagement practices by conducting in-depth, semi-structured interviews with 24 hour service providers in a Midwest region. Findings Practitioners discussed a wide variety of perceptions of motivational interviewing, ranging from completely unfamiliar, to inapplicable to their service population, to favoring its use. Those who did implement motivational interviewing described challenges to engagement with this population and provided examples in which they did not validate the clients’ perceived benefits of situations that enhanced their risk, a principal tenant of motivational interviewing. Such actions may have contributed to practitioner-client discord and ultimately reduced clients’ engagement. Applications Providers who encounter sex trafficking in practice should be trained in the use of motivational interviewing and applicability, specifically regarding how to validate the client’s internal arguments for and against sex trading and related behaviors. Future research should continue to understand whether and how motivational interviewing can be adapted for transient populations, and continue testing the efficacy of motivational interviewing with these populations.
Three-Year Follow-up of Patients With Iliac Occlusive Disease Treated With the Viabahn Balloon- Expandable Endoprosthesis
Authors: Panneton Jean M. , Bismuth Jean , Gray Bruce H. , Holden Andrew 
Published: April 2020

Purpose: To assess the midterm safety and effectiveness of the Gore Viabahn Balloon-Expandable Endoprosthesis (VBX Stent-Graft) in the treatment of patients with de novo or restenotic aortoiliac lesions. Materials and Methods: The prospective, multicenter, nonrandomized, single-arm VBX FLEX clinical study ( ClinicalTrials.gov identifier: NCT02080871) evaluated 134 patients (mean age 66±9.5 years; 79 men) up to 3 years after treatment with the VBX Stent-Graft. A total of 213 lesions were treated with 234 stent-grafts. The primary safety endpoint was a composite of major adverse events (MAEs), which were evaluated through 30 days and 9 months. Secondary outcomes collected through 3 years included freedom from target lesion revascularization (TLR), target vessel revascularization (TVR), clinically-driven TLR (CD-TLR), and CD-TVR as well as Rutherford category, resting ankle-brachial index (ABI), and functional status. A univariate analysis determined any correlation between baseline variables and TLR. Results: The observed composite percentage of MAEs was 2.3%, well below the 17% performance goal (p<0.001). Of the 134 patients in the per protocol analysis, 107 (80%) completed the study. The 1-year Kaplan-Meier estimate of primary patency was 94.5% and primary assisted patency was 99.0%. The estimate of freedom from TLR per-lesion/vessel was 97.6% at 9 months and 91.2% at 3 years. The 9-month estimate of freedom from CD-TLR was 98.6% and the 3-year estimate was 98.1%. The 3-year mean resting ABI was 0.93±0.19, an improvement of 0.17±0.26 from baseline (p<0.001). At 3 years, 82 patients (92.1%) improved ≥1 Rutherford category from baseline, and 77 patients (86.5%) maintained or improved upon their baseline functional status. Conclusion: The VBX Stent-Graft is a robust and durable treatment option for aortoiliac occlusive disease as evidenced by the sustained 3-year safety and effectiveness outcomes.
Role of the mitochondrial stress response in human cancer progression
Authors: Wang Sheng-Fan , Chen Shiuan , Tseng Ling-Ming , Lee Hsin-Chen 
Published: April 2020

Mitochondria are important organelles that are responsible for cellular energy metabolism, cellular redox/calcium homeostasis, and cell death regulation in mammalian cells. Mitochondrial dysfunction is involved in various diseases, such as neurodegenerative diseases, cardiovascular diseases, immune disorders, and cancer. Defective mitochondria and metabolism remodeling are common characteristics in cancer cells. Several factors, such as mitochondrial DNA copy number changes, mitochondrial DNA mutations, mitochondrial enzyme defects, and mitochondrial dynamic changes, may contribute to mitochondrial dysfunction in cancer cells. Some lines of evidence have shown that mitochondrial dysfunction may promote cancer progression. Here, several mitochondrial stress responses, including the mitochondrial unfolded protein response and the integrated stress response, and several mitochondrion-derived molecules (reactive oxygen species, calcium, oncometabolites, and others) are reviewed; these pathways and molecules are considered to act as retrograde signaling regulators in the development and progression of cancer. Targeting these components of the mitochondrial stress response may be an important strategy for cancer treatment.Impact statementDysregulated mitochondria often occurred in cancers. Mitochondrial dysfunction might contribute to cancer progression. We reviewed several mitochondrial stresses in cancers. Mitochondrial stress responses might contribute to cancer progression. Several mitochondrion-derived molecules (ROS, Ca2+, oncometabolites, exported mtDNA, mitochondrial double-stranded RNA, humanin, and MOTS-c), integrated stress response, and mitochondrial unfolded protein response act as retrograde signaling pathways and might be critical in the development and progression of cancer. Targeting these mitochondrial stress responses may be an important strategy for cancer treatment.
Role of hyperoxic treatment in cancer
Authors: Kim Sei W , Kim In K , Lee Sang H 
Published: April 2020

The occurrence of hypoxia is common in many solid tumors, and it enhances aggressive features of cancer such as cell survival, angiogenesis, and metastasis while minimizing the efficacies of chemotherapy and radiotherapy. Hypoxia also plays a pivotal role in regulating immune cell function which is important for immunotherapy. Hypoxia-inducible factor has been suggested as a master regulator of tumor cell adaptation to the hypoxic microenvironment. Currently, several approaches have been proposed to eliminate the hypoxic state in tumors for delaying cancer progression and improving therapeutic efficacy. In this review, we summarize current findings on the relevance of hyperoxia-based therapeutics for cancer treatment. Accumulating evidence indicates that hyperoxic therapy inhibits tumor growth and increases treatment efficacy. Primary antitumor effect of hyperoxic therapy may be due to the reversal of tumor hypoxia and the generation of reactive oxygen species. Restoring immune function is also suggested as a potential mechanism. Hyperoxic therapy can also cause cellular injury and organ dysfunction. In conclusion, overcoming tumor hypoxia is a major problem that needs to be solved. Further studies to standardize and personalize hyperoxia therapy according to the type of cancer, stage, and comorbidities are needed. Impact statement Tumor hypoxia promotes cancer cell aggressiveness, and is strongly associated with poor prognosis across multiple tumor types. The hypoxic microenvironments inside tumors also limit the effectiveness of radiotherapy, chemotherapy, and immunotherapy. Several approaches to eliminate hypoxic state in tumors have been proposed to delay cancer progression and improve therapeutic efficacies. This review will summarize current knowledge on hyperoxia, used alone or in combination with other therapeutic modalities, in cancer treatment. Molecular mechanisms and undesired side effects of hyperoxia will also be discussed.
Surgical results in older patients with lumbar spinal stenosis according to gait speed in relation to the diagnosis for sarcopenia
Authors: Sakai Yoshihito , Wakao Norimitsu , Matsui Hiroki , Tomita Keisuke , Watanabe Tsuyoshi , Iida Hiroki 
Published: April 2020

Purpose: The purpose of this study was to evaluate the implication of gait speed, which is a prerequisite for the diagnosis of sarcopenia in older patients with lumbar spinal stenosis (LSS). Methods: This study was conducted in a total of 235 patients with LSS who underwent surgical treatment. The state of sarcopenia and pre-sarcopenia, including gait speed, were evaluated before and after the operation. Results: The proportion of patients with lower than at baseline levels of skeletal muscle mass index (SMI) and gait speed was 27.2% and 17.9%, respectively. Significant changes were observed in gait speed, whereas SMI showed no significant differences between the preoperative and postoperative periods. Sarcopenic patients presented lower levels of activities of daily living preoperatively than pre-sarcopenic patients. However, favorable surgical results were obtained postoperatively. Significant changes were observed in gait speed, whereas grip strength and SMI showed no significant differences between the preoperative and postoperative periods. The postoperative decrease in SMI was not significant. Conclusion: Postoperative gait speed was significantly improved, whereas muscle mass did not increase in the patients in this study. Therefore, low gait speed in patients with LSS seems to be derived from a neurologic disorder. The surgical results in low muscle mass patients without low gait speed were similar to those with low gait speed. Sarcopenia in elderly patients with locomotor disease should be evaluated using muscle mass alone without assessing physical performance.
Knowledge About Sexual and Reproductive Health in Adolescent School-Going Children of 8th, 9th, and 10th Standards
Authors: Deshmukh Deepanjali D. , Chaniana Sukhjeet S. 
Published: April 2020

Context: Adolescence is a transitional period that marks the beginning of adulthood and is a stage in life in which an individual attains sexual maturity. Adolescent’s decisions and behavior related to sexual matters can have long-lasting implications, and if wrongly informed, they can suffer adverse consequences. Aim: The study was conducted to assess the level of knowledge about reproductive and sexual health, the knowledge and attitude about sex-related illnesses, and the level of knowledge about common changes of secondary sexual characters among adolescents. Methodology: 300 adolescent students of 8th, 9th, and 10th standards were selected after taking permission from the school principal and consent from the parents/guardians of the students. Samples were collected from 2 Central Board of Secondary Education schools. 50 students of each standard were randomly selected from the school and were assessed using semistructured pro forma containing questions about sociodemographic profile and knowledge and attitude toward sexual issues. Data thus collected was tabulated and statistically analyzed under the guidance of a statistician. Results and Conclusion: Girls were found to have less knowledge compared to boys. Higher the standard the student was in, more the level of knowledge; 10th standard students had more knowledge compared to 9th and 8th standard students. Parents need to have adequate communication with their adolescents regarding sex-related topics as parents were found to be among the least common source of information, while teachers were the most common source of information regarding the topic.
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Authors: Lancet Jeffrey E. , Moseley Anna B. , Coutre Steven E. , DeAngelo Daniel J. , Othus Megan , Tallman Martin S. , Litzow Mark R. , Komrokji Rami S. , Erba Harry P. , Appelbaum Frederick R. 
Published: April 2020

Abstract
High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is a well-established treatment for patients with standard-risk APL, but it is not well defined for those with high-risk APL. In a prior study of patients with high-risk APL, the addition of gemtuzumab ozogamicin (GO) to ATO plus ATRA suggested benefit. The SWOG Cancer Research Network conducted a phase 2 study to confirm the efficacy and safety of the combination of ATRA plus ATO plus GO in treating high-risk APL patients. The primary end points were 3-year event-free survival (EFS) and early (6-week) death rates associated with this combination. Seventy patients were treated. With a median follow-up of 3.4 years, the 3-year EFS and overall survival estimates were 78% (95% confidence interval [CI], 67%-86%) and 86% (95% CI, 75%-92%), respectively. Overall, 86% of patients achieved complete response. The 6-week mortality rate was 11%. The most common treatment-emergent toxicities during the induction phase included febrile neutropenia, aspartate aminotransferase/alanine aminotransferase elevation, hyperglycemia, hypoxia, headache, and prolonged QT interval corrected for heart rate. Retinoic acid syndrome occurred in 9% of patients. Approximately 37% of patients did not complete all planned courses of postremission therapy. The combination of ATRA plus ATO plus GO in high-risk APL patients was effective and generally well tolerated, suggesting an opportunity to offer a chemotherapy-free induction platform for patients with this disease. This trial was registered at www.clinicaltrials.gov as #NCT00551460.
Obituary for Tamara Grummt
Authors: Braunbeck Thomas , Erdinger Lothar , Frimmel Fritz H. , Hollert Henner , Knasmüller Siegfried , DeMarini David M. , Plewa Michael J. , Richardson Susan D. , Triebskorn Rita , de Aragão Umbuzeiro Gisela , White Paul A. 
Published: April 2020

AbstractTamara Grummt passed away on January 26, 2020 in Oelsnitz/Vogtland, Germany. Tamara was one of the scientific pioneers in the field of environmental toxicology, namely genotoxicity and hygiene of drinking and bathing waters. Her passing is not only a great loss to environmental research and to the global environmental toxicology community—we have lost an outstanding personality with the heart in the right place, who has become, for many of us, a wonderful friend.
Correction to: Determinants of none-exclusive breast feeding practice among HIV positive women at selected Health Institutions in Ethiopia: case control study
Authors: Ayele Aklilu Abera , Seid Kemal Ahmed , Muhammed Oumer Sada 
Published: April 2020

The authorship list on the original article [1] was incorrect and should instead show as Aklilu Abera Ayele, Kemal Ahmed Seid and Oumer Sada Muhammed. The authors apologise for this error.
Awareness of mycotoxins and occurrence of aflatoxins in poultry feeds and feed ingredients in selected regions of Uganda
Authors: Nakavuma Jesca L. , Kirabo Angella , Bogere Paul , Nabulime Margaret M. , Kaaya Archileo N. , Gnonlonfin Benoit 
Published: April 2020

AbstractBackgroundAflatoxins are a category of mycotoxins produced by certain molds naturally occurring as food and feed contaminants with toxic effects to both animals and humans. In Uganda, previous studies on aflatoxins mainly considered human foods, but scarce information exists for animal feeds. The study aimed at establishing the current status of aflatoxins contamination of poultry feeds, level of awareness and the existing technological challenges and innovations to mycotoxin control in Uganda.MethodMycotoxin awareness, predisposing factors and existing strategies for managing mycotoxin contamination were investigated through focus group discussions and questionnaires with selected processors and farmers. Poultry feed and feed ingredient samples were collected and analyzed for total aflatoxins using VICAM Fluorimeter procedure for foods and animal feeds.ResultsMajority of the farmers and processors (> 50%) had limited knowledge about aflatoxins; contamination predisposing factors; dangers to animals and humans; and mitigation strategies. The study further revealed poor feed and feed ingredients handling and storage practices that predispose to mold/aflatoxin contamination. Forty feed samples from feed processing plants had aflatoxins in the range 7.5 ± 0.71 to 393.5 ± 19.09 parts per billion (ppb) with only twelve samples being within the generally acceptable limits of 20 ppb as recommended by the Food and Agricultural Organisation and the United States Federal Department of Agriculture. Additionally, all 27 feed samples obtained from the farmers had aflatoxins in the range of 19.0 ± 1.41 to 188.5 ± 2.12 ppb and were above the acceptable limit. Generally, broiler feeds were the most contaminated with aflatoxins. Of the feed ingredients tested, silver fish (Rastrineobola argentea, locally known as “mukene”) had the least concentration (8.7 ± 3.18 ppb) of aflatoxins while maize bran had the highest level of contamination, 103.3 ± 22.98 ppb.ConclusionGiven the lack of awareness and the high prevalence of aflatoxin contaminated poultry feeds and feed ingredients in Uganda, a higher risk for carryover of the toxins into the animal products for human consumption exist. Hence, the need for comprehensive establishment of the prevention, control and surveillance strategies for reducing mycotoxins in foods.
Can contrast-enhanced mammography replace dynamic contrast-enhanced MRI in the assessment of sonomammographic indeterminate breast lesions?
Authors: Kamal Rasha Mohamed , Hanafy Mennatallah Mohamed , Mansour Sahar Mahmoud , Hassan Maher , Gomaa Mohamed Mohamed 
Published: April 2020

AbstractBackgroundDynamic contrast-enhanced MRI of the breast has been used for several years in the assessment of indeterminate mammographic findings. Contrast-enhanced mammography is a relatively novel imaging technique that has shown comparable sensitivity and specificity to MRI. Contrast-enhanced mammography is a relatively easy feasible study with high sensitivity and low cost. Our aim was to assess the feasibility of replacing dynamic contrast-enhanced (DCE)-MRI by contrast-enhanced mammography in the assessment of sonomammographic indeterminate lesions (BIRADS 3 and 4).ResultsThe study included 82 patients with 171 breast lesions. They all performed contrast-enhanced mammography and dynamic contrast-enhanced MRI. DCE-MRI sensitivity and NPV were significantly higher than those of contrast-enhanced mammogram (CEM). The overall accuracy of MRI was better than that of CEM; however, no statistically significant difference could be detected.ConclusionContrast-enhanced mammography and dynamic contrast-enhanced MRI improved the characterization of breast lesions. CEM showed slightly lower sensitivity and accuracy compared to MRI; however, because of being relatively easy, available, cheap, and acceptable by women, CEM can replace DC-MRI as a problem-solving tool in the characterization of indeterminate breast lesions.
CLASPs at a glance
Authors: Lawrence Elizabeth J. , Zanic Marija , Rice Luke M. 
Published: April 2020

ABSTRACT
CLIP-associating proteins (CLASPs) form an evolutionarily conserved family of regulatory factors that control microtubule dynamics and the organization of microtubule networks. The importance of CLASP activity has been appreciated for some time, but until recently our understanding of the underlying molecular mechanisms remained basic. Over the past few years, studies of, for example, migrating cells, neuronal development, and microtubule reorganization in plants, along with in vitro reconstitutions, have provided new insights into the cellular roles and molecular basis of CLASP activity. In this Cell Science at a Glance article and the accompanying poster, we will summarize some of these recent advances, emphasizing how they impact our current understanding of CLASP-mediated microtubule regulation.
Effect of different biofloc starters on ammonia, nitrate, and nitrite concentrations in the cultured tilapia Oreochromis niloticus system
Authors: Putra Iskandar , Effendi Irwan , Lukistyowati Iesje , Tang Usman M. , Fauzi Muhammad , Suharman Indra , Muchlisin Zainal A. 
Published: April 2020

Background: High stocking density and intensive feeding in aquaculture systems lead to the accumulation of organic waste, which results in an increase in ammonia, nitrite, and nitrite concentrations in culture media. Biofloc is a potential technology to overcome this problem. The starter is a crucial carbon source for bacteria in the formation of biofloc. The objective of the present study aimed to explore the best starter of biofloc in a red tilapia Oreochromis niloticus culture system. Methods: A completely randomized design with four levels of treatment was used in this study. The tested starter was (A) control treatment, biofloc without starter, (B) biofloc with molasses starter, (C) biofloc with tapioca starter, and (D) biofloc with sucrose starter. The floc was cultured in 100-L tanks with a salinity of 17 ppt. The tanks were stocked with O. niloticus with a size of 3.71±0.11 cm at a stocking density of 30 fish per tank. The fish were fed on a commercial diet two times a day at satiation for 40 days. The ammonia, nitrite, and nitrite concentrations were measured for an interval of 8 days. Results: The study showed that the NH3-N range was 0.02–0.07 mg L−1 (mean, 0.03 ± 0.02 mg L−1), NO2-N range was 0.20–0.43 mg L−1 (mean, 0.25 ± 0.12 mg L−1), and NO3-N range was 0.90–3.20 mg L−1 (mean, 1.42 ± 1.19 mg L−1). Conclusion: Among the starters tested, molasses was found to be the best for biofloc in tilapia culture.
Improving causality in microbiome research: can human genetic epidemiology help?
Authors: Wade Kaitlin H. , Hall Lindsay J. 
Published: April 2020

Evidence supports associations between human gut microbiome variation and multiple health outcomes and diseases. Despite compelling results from in vivo and in vitro models, few findings have been translated into an understanding of modifiable causal relationships. Furthermore, epidemiological studies have been unconvincing in their ability to offer causal evidence due to their observational nature, where confounding by lifestyle and behavioural factors, reverse causation and bias are important limitations. Whilst randomized controlled trials have made steps towards understanding the causal role played by the gut microbiome in disease, they are expensive and time-consuming. This evidence that has not been translated between model systems impedes opportunities for harnessing the gut microbiome for improving population health. Therefore, there is a need for alternative approaches to interrogate causality in the context of gut microbiome research. The integration of human genetics within population health sciences have proved successful in facilitating improved causal inference (e.g., with Mendelian randomization [MR] studies) and characterising inherited disease susceptibility. MR is an established method that employs human genetic variation as natural “proxies” for clinically relevant (and ideally modifiable) traits to improve causality in observational associations between those traits and health outcomes. Here, we focus and discuss the utility of MR within the context of human gut microbiome research, review studies that have used this method and consider the strengths, limitations and challenges facing this research. Specifically, we highlight the requirements for careful examination and interpretation of derived causal estimates and host (i.e., human) genetic effects themselves, triangulation across multiple study designs and inter-disciplinary collaborations. Meeting these requirements will help support or challenge causality of the role played by the gut microbiome on human health to develop new, targeted therapies to alleviate disease symptoms to ultimately improve lives and promote good health.